Perioperative blood transfusion has a dose-dependent relationship with disease recurrence and survival in patients with non-small cell lung cancer

被引:31
|
作者
Latif, M. Jawad [1 ]
Tan, Kay See [2 ]
Molena, Daniela [1 ]
Huang, James [1 ]
Bott, Matthew J. [1 ]
Park, Bernard J. [1 ]
Adusumilli, Prasad S. [1 ]
Rusch, Valerie W. [1 ]
Bains, Manjit S. [1 ]
Downey, Robert J. [1 ]
Jones, David R. [1 ]
Isbell, James M. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Thorac Surg Serv, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
来源
基金
美国国家卫生研究院;
关键词
transfusion; lung cancer; lobectomy; segmentectomy; survival; propensity-score matching; recurrence; LIMITED RESECTION; SURGERY; PROGNOSIS; LOBECTOMY; IMPACT;
D O I
10.1016/j.jtcvs.2018.12.109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Perioperative blood transfusions have been implicated in decreased overall survival (OS) and disease-free survival (DFS) after resection for non-small cell lung cancer (NSCLC). We investigated the effects of single- and multiple-unit blood transfusions on OS, DFS, and recurrence after anatomic pulmonary resection. Methods: From January 1, 2000, to June 30, 2016, 5709 consecutive patients underwent pulmonary resection for NSCLC at our institution. Exclusion criteria were stage IIIB-IV disease, incomplete resections, ill-defined histologic subtypes, and nonanatomic wedge resections. For the 0 versus single-unit analysis, propensity scores were calculated from a logistic regression model that predicted the probability of patients receiving a single-unit transfusion. The resulting matching weights were incorporated into Cox models for OS, DFS, and cumulative incidence of recurrence, to compare no versus single-unit blood transfusion. We determined whether increasing numbers of blood transfusions influenced survival or recurrence using multivariable Cox models. Results: Approximately 10% of patients received perioperative blood transfusion (median follow-up, 7.46 years [25th-75th percentile, 3.98-11.8]). There was no difference in OS, DFS, or cumulative incidence of recurrence between patients receiving no transfusion and those receiving single-unit transfusion (P > .05). However, a dose-response relationship was observed, demonstrating worse OS (overall P < .001), DFS (overall P < .001), and recurrence (overall P = .010) with increasing units of blood transfused. Conclusions: Although a single-unit blood transfusion did not affect survival in patients undergoing resection for NSCLC, greater unit perioperative blood transfusions were associated with significantly decreased long-term outcomes in a dose-dependent manner, suggesting avoidance or minimization of transfusions could improve long-term survival after lung resection.
引用
收藏
页码:2469 / +
页数:19
相关论文
共 50 条
  • [11] Chemotherapy Dose Intensity and Survival in Non-small Cell Lung Cancer
    Stewart, David J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) : 971 - 971
  • [12] SBRT Dose and Survival in Non-Small Cell Lung Cancer Reply
    Koshy, Matthew
    Sher, David J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (04): : 946 - 947
  • [13] Predictors of Survival in Patients With Non-Small Cell Lung Cancer
    Luo, Juhua
    Chen, Yea-Jyh
    Narsavage, Georgia L.
    Ducatman, Alan
    ONCOLOGY NURSING FORUM, 2012, 39 (06) : 609 - 616
  • [14] Factors impacting survival of patients with post-surgical disease recurrence in non-small cell lung cancer (NSCLC).
    Banerji, S.
    Nugent, Z.
    Demers, A.
    Navaratnam, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 419S - 419S
  • [15] Influence of blood transfusions and perioperative anemia on long-term survival in patients operated for non-small cell lung cancer
    Panagopoulos, N.
    Koletsis, E.
    Karakantza, M.
    Sakellaropoulos, G.
    Filos, K.
    Apostolakis, E.
    Dougenis, D.
    LUNG CANCER, 2007, 55 : S14 - S14
  • [16] Perioperative Immunotherapy in Non-Small Cell Lung Cancer
    Jenny O’Brien
    J. Nicholas Bodor
    Current Treatment Options in Oncology, 2023, 24 : 1790 - 1801
  • [17] Non-small cell lung cancer: Perioperative treatments
    Westeel, Virginie
    Schipman, Benjamin
    Jacoulet, Pascale
    PRESSE MEDICALE, 2011, 40 (04): : 398 - 403
  • [18] Perioperative Immunotherapy in Non-Small Cell Lung Cancer
    O'Brien, Jenny
    Bodor, J. Nicholas
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1790 - 1801
  • [19] Perioperative Nivolumab in non-small cell Lung Cancer
    Lorenz, Judith
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (18) : 1065 - 1066
  • [20] Effect of leucodepletion and perioperative blood transfusion on survival and recurrence in gastrointestinal cancer patients
    van Hilten, J. A.
    Lange, M. M.
    van de Watering, L. M. G.
    van de Velde, C. J. H.
    Brand, A.
    VOX SANGUINIS, 2008, 95 : 12 - 12